EGLT - Egalet Corporation

YHD - YHD Delayed Price. Currency in USD
At close: 6:07PM EDT
Stock chart is not supported by your current browser
Previous CloseN/A
YTD ReturnN/A
Expense Ratio (net)N/A
CategoryN/A
Last Cap GainN/A
Morningstar RatingN/A
Morningstar Risk RatingN/A
Sustainability RatingN/A
Net AssetsN/A
Beta (3Y Monthly)N/A
YieldN/A
5y Average ReturnN/A
Holdings TurnoverN/A
Last DividendN/A
Average for CategoryN/A
Inception DateN/A
  • Thomson Reuters StreetEvents

    Edited Transcript of EGLT earnings conference call or presentation 13-Aug-19 8:30pm GMT

    Q2 2019 Zyla Life Sciences Earnings Call

  • Thomson Reuters StreetEvents

    Edited Transcript of EGLT earnings conference call or presentation 16-May-19 8:30pm GMT

    Q1 2019 Egalet Corp Earnings Call

  • Associated Press

    Egalet: 3Q Earnings Snapshot

    The Wayne, Pennsylvania-based company said it had a loss of 93 cents per share. Losses, adjusted for one-time gains and costs, were 75 cents per share. The pain medicine maker posted revenue of $8.2 million ...

  • Egalet Reports Third Quarter 2018 Financial Results
    PR Newswire

    Egalet Reports Third Quarter 2018 Financial Results

    -- Highest quarterly revenue for SPRIX Nasal Spray and OXAYDO -- WAYNE, Pa. , Nov. 19, 2018 /PRNewswire/ -- Egalet Corporation (Nasdaq: EGLT) ("Egalet"), a fully integrated specialty pharmaceutical ...

  • Will Egalet (EGLTQ) Report Negative Earnings Next Week? What You Should Know
    Zacks

    Will Egalet (EGLTQ) Report Negative Earnings Next Week? What You Should Know

    Egalet (EGLTQ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Zacks Small Cap Research

    EGLT: Egalet Recapitalization

    On October 31, 2018 Egalet Corp (EGLT) announced that it has signed a purchase agreement to acquire several pain products from Iroko Pharmaceuticals, Inc. (private). With insufficient cash to satisfy the outstanding debt, Egalet entered into forbearance with noteholders leading to the Chapter 11 filing. If the proposed asset purchase agreement is approved, Egalet will acquire several assets from Iroko, including Vivlodex, Tivorbex, Zorvolex, Indocin and an in-development NSAID.

  • Egalet Signs Asset Purchase Agreement to Acquire Four FDA-Approved, Non-Narcotic Pain Products
    PR Newswire

    Egalet Signs Asset Purchase Agreement to Acquire Four FDA-Approved, Non-Narcotic Pain Products

    WAYNE, Pa., Oct. 31, 2018 /PRNewswire/ -- Egalet Corporation (EGLT) ("Egalet"), a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative treatments for pain, today entered into an asset purchase agreement to acquire four marketed products from Iroko Pharmaceuticals, Inc. (Iroko). If consummated, the proposed transaction will enable Egalet to focus on marketing predominantly non-narcotic pain products. To facilitate this transaction and reorganize Egalet's capital structure, Egalet has initiated proceedings under Chapter 11 of the United States Bankruptcy Code in the District of Delaware.